BioSpace News Archive

The Board of Directors of Cigna Corporation declared a cash dividend of $1.12 per share of Cigna common stock, payable on September 22, 2022 to shareholders of record as of the close of business on September 7, 2022.

Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, today announced the validation of a laboratory developed test (LDT) to quantitatively measure phospho-Tau 181 (pTau-181) in plasma as an aid in diagnostic evaluation of Alzheimer’s disease (AD).

Terumo Blood and Cell Technologies (Terumo), a medical technology company, and Eliaz Therapeutics Inc. (ETI), a medical device company, today announced an exclusive collaboration to help combat AKI and S-AKI by focusing on the selective removal of an upstream inflammatory protein called Galectin-3 (Gal-3) from blood plasma.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022, after the market closes.

Health Canada is providing an update on the progress of Philips Respironics’ recall of several models of CPAP and BiLevel PAP machines and mechanical ventilators in Canada.

OneTouchPoint, Inc. (“OTP”) is providing notice of an incident that may affect the privacy of certain individuals’ personal information.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the interim safety and efficacy data of dose expansion cohort from the phase I study of TST001.

According to the report, the global antithrombin treatment market was valued at US$ 0.50 Bn in 2022 and is anticipated to expand at a CAGR of 5.3% from 2022 to 2030.

The global cell culture media, sera, and reagents market was valued at US$ 4.9 Bn in 2022 and is anticipated to expand at a CAGR of 5.7% from 2022 to 2030.

According to the report, the global hemostasis diagnostics market was valued at US$ 2.3 Bn in 2022 and is anticipated to expand at a CAGR of 8.5% from 2022 to 2030.